SCHEMBL4085268

SCHEMBL4085268

CCOC(=O)N1CCN(c2nc(-c3ccc(C(C)(C)C)cc3)nc3ccc(OC)cc23)CC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.52
LMNA P02545 2/20 0.52
NPC1 O15118 1/20 0.52
HTT P42858 1/20 0.52
MEN1 O00255 4/20 0.49
KMT2A Q03164 4/20 0.49
KDM4E B2RXH2 3/20 0.49
HPGD P15428 2/20 0.49
ALDH1A1 P00352 1/20 0.49
IDE P14735 1/20 0.49
HIF1A Q16665 1/20 0.49
RAB9A P51151 1/20 0.48
NTSR1 P30989 3/20 0.47
SMN1; SMN2 Q16637 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
MTNR1B P49286 1/20 0.46
TP53 P04637 2/20 0.45
ABCG2 Q9UNQ0 1/20 0.45
P2RY12 Q9H244 1/20 0.44
HRH2 P25021 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4093185 0.89 MEN1 (0.51) HTTMEN1KMT2AKDM4EALDH1A1
SCHEMBL4085181 0.88 MEN1 (0.49) MAPTLMNAHTTMEN1KMT2A
SCHEMBL4095930 0.86 MEN1 (0.66) MAPTLMNANPC1MEN1KMT2A
SCHEMBL4098753 0.83 KDM4E (0.57) MEN1KMT2AKDM4ERAB9ANTSR1
SCHEMBL4090457 0.80 ALDH1A1 (0.48) MAPTLMNANPC1HTTMEN1
SCHEMBL4085061 0.80 MEN1 (0.53) MAPTLMNANPC1HTTMEN1
SCHEMBL4097266 0.80 MAPT (0.59) MAPTLMNANPC1HTTMEN1
SCHEMBL4097528 0.80 MEN1 (0.54) MAPTLMNAHTTMEN1KMT2A
SCHEMBL4100017 0.78 KMT2A (0.52) MAPTHTTMEN1KMT2AKDM4E
SCHEMBL4096410 0.76 NTSR1 (0.59) MAPTLMNAMEN1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2009-08-20 US disclosed
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2009-08-20 US disclosed
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2009-08-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE CNR2, CNR1, GPR18 MAPT 4125/4885LMNA 2728/4885NPC1 1047/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.